Article
Dermatology
Claudio Bonifati, Aldo Morrone, Antonio Cristaudo, Dario Graceffa
Summary: New biologic drugs targeting interleukin-17 have shown quick effectiveness in treating psoriasis, but there is limited real-life data on switching to biologics targeting interleukin-23 in patients who have failed previous treatments.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
Sophia Z. Shalhout, Romi Bloom, Lynn Drake, David M. Miller
Summary: The study evaluated the fragility of clinical trial data used to support FDA approval of therapies for psoriasis and found that pivotal trials in psoriasis appear quite robust to changes in outcomes compared with randomized controlled trials for FDA approval across various diseases.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Review
Immunology
Angela Ceribelli, Francesca Motta, Matteo Vecellio, Natasa Isailovic, Francesco Ciccia, Carlo Selmi
Summary: Spondyloarthritis (SpA) is a group of inflammatory musculoskeletal diseases with common genetic backgrounds, and IL-17 and IL-23 have been identified as key cytokines in its pathogenesis. Treatment options for axial SpA differ significantly from peripheral arthritis, with new therapies targeting these cytokines showing promising results for both axial psoriatic arthritis and ankylosing spondylitis.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Sindhuja Koppu, Rohan Singh, Kiranjit Kaur, Steven R. Feldman
Summary: Bimekizumab, a promising treatment for moderate-to-severe plaque psoriasis, has shown efficacy and tolerability in clinical trials.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Biochemistry & Molecular Biology
Yu-Huei Huang, Lun-Ching Chang, Ya-Ching Chang, Wen-Hung Chung, Shun-Fa Yang, Shih-Chi Su
Summary: Alterations in gut microbiota composition and microbial-encoded metabolic pathways were observed in patients with psoriasis, and the impact of biologics on shaping gut microbiota was explored in this study. The results showed that the gut microbial compositions changed during the treatment period, and the relative abundance of individual taxa differed between patients receiving different inhibitors.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Medicine, General & Internal
Gianluca Avallone, Carlo Alberto Maronese, Giulia Murgia, Carlo Giovanni Carrera, Luca Mastorino, Gabriele Roccuzzo, Paolo Dapavo, Silvia Alberti-Violetti, Pietro Quaglino, Simone Ribero, Angelo Valerio Marzano
Summary: This study aimed to compare the efficacy of IL-17 and IL-23 inhibitors in treating pustular and erythrodermic psoriasis. The results showed that IL-17 inhibitors had higher effectiveness in treating these conditions, while the efficacy of IL-23 inhibitors remains unknown.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Evelyn Kelemen, Eva Adam, Stella Marta Sagi, Aniko Goblos, Lajos Kemeny, Zsuzsanna Bata-Csorgo, Marta Szell, Judit Danis
Summary: Psoriasis is a chronic inflammatory skin disease influenced by both genetic and environmental factors. Increased levels of free nucleic acids in psoriatic skin are associated with IL-23 expression. The study reveals that free nucleic acids regulate IL-23 mRNA expression in epithelial keratinocytes through TLR3 receptor and specific signaling pathways, contributing to the development of an inflammatory milieu favorable for psoriatic symptoms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Microbiology
Zhao Liu, Qing Liu, Yanyan Xu, Zhao Han, Ling Zhang, Xiaojing Li
Summary: This study aimed to investigate the effect and mechanism of 3% boric acid solution (BAS) on Candida albicans (CA) infection, and found that IL-17, IL-22, and IL-23 are involved in the anti-CA activity in mouse skin, and 3% BAS increased IL-17, IL-22, and IL-23 levels to mediate these effects.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Dermatology
Xingyu Zhu, Ruomei Han, Xiaoxue Tian, Mathias Hochgerner, Hui Li, Jiucun Wang, Jingjing Xia
Summary: Tapinarof has different effects on different types of psoriasis, inhibiting the development of IMQ-induced psoriatic dermatitis while aggravating the IL-23-injection model. This suggests that Tapinarof may have varying effects on different psoriasis subtypes.
EXPERIMENTAL DERMATOLOGY
(2023)
Article
Dermatology
Hidehisa Saeki, Tomotaka Mabuchi, Akihiko Asahina, Masatoshi Abe, Atsuyuki Igarashi, Shinichi Imafuku, Yukari Okubo, Mayumi Komine, Shigetoshi Sano, Hideshi Torii, Akimichi Morita, Hiroshi Yotsuyanagi, Akira Watanabe, Mamitaro Ohtsuki
Summary: This article provides an overview of the development of biologics for psoriasis treatment in Japan and emphasizes the importance of considering factors such as efficacy, safety, convenience, and cost when selecting biologic therapies for patients.
JOURNAL OF DERMATOLOGY
(2022)
Review
Dermatology
Jeremy G. Light, Jennifer J. Su, Steven R. Feldman
Summary: Psoriasis, a chronic immune-mediated disease, involves complex interactions between T cells and keratinocytes. The IL-23/Th17 pathway plays a central role in the development of the disease, with guselkumab targeting the p19 subunit of IL-23 as a first-line treatment option for moderate-to-severe psoriasis. Recent head-to-head trials have demonstrated the long-term efficacy, safety, and improved quality of life in patients treated with guselkumab, solidifying its position as a viable treatment option.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Alan Vu, Caden Ulschmid, Kenneth B. Gordon
Summary: This article reviews the IL-23/Th17 axis and IL-23 inhibitors as therapeutic targets for a growing family of biologics in the treatment of psoriasis. These include FDA-approved medications such as ustekinumab, guselkumab, tildrakizumab, and risankizumab. The safety and efficacy of these medications in moderate-to-severe psoriasis are discussed based on various Phase 1, 2, and 3 trials. A literature search of PubMed was conducted using keywords such as 'psoriasis and IL-23,' 'ustekinumab,' 'guselkumab,' 'tildrakizumab,' and 'risankizumab.' Clinical trials involving IL-23 inhibitors registered at ClinicalTrials.gov were also searched.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2022)
Article
Multidisciplinary Sciences
Charles S. Lay, Albert Isidro-Llobet, Laura E. Kilpatrick, Peter D. Craggs, Stephen J. Hill
Summary: Using a fluorescent version of IL-23, this study characterized antagonists of the full-length receptor expressed by living cells and developed a cyclic peptide fluorescent probe specific to the IL23p19:IL23R interface to further study receptor antagonists. The study also demonstrated that the immunocompromising C115Y IL23R mutation disrupts the binding epitope for IL23p19.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, General & Internal
Dawei Huang, Yingyuan Yu, Jiajing Lu, Fei Tan, Yuling Shi
Summary: The study found that compared to tumor necrosis factor-alpha inhibitors (TNF-alpha i), interleukin-17 inhibitors (IL-17i) and interleukin-23 inhibitors (IL-23i) have a protective effect on psoriasis flare-up. Additionally, an increased proportion of people with worsened psoriasis developed long COVID-19, suggesting worsened psoriasis may be a potential risk factor for long COVID-19.
FRONTIERS IN MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Aikaterini Tsiogka, Stamatios Gregoriou, Alexander Stratigos, Stergios Soulaidopoulos, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Anna Campanati, Annamaria Offidani, Charalambos Vlachopoulos, Dimitrios Rigopoulos
Summary: Accumulating evidence suggests that psoriasis, a systemic inflammatory disorder, is associated with comorbidities such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. Chronic systemic inflammation and T helper (Th)-1 and Th17 polarization are believed to be associated with endothelial dysfunction and accelerated atherosclerosis. This systematic review summarizes the current understanding of the pathogenesis and diagnostic evaluation of atherosclerosis in psoriasis, and reviews the impact of IL-23/Th17 axis-targeted biologic treatments on subclinical atherosclerosis in patients with psoriasis and/or psoriatic arthritis.
